Adam knows that most if not all CANCER trials of small biotech companies fail. He is bashing them all and that is where his "guru" reputation comes from. How is his track record in non-oncology drugs?
But, with Zerenex he has been dead wrong. He didn't saw anemia and iron benefits of ferric citrate.
Look at his mailbag 01/25/13 (friday before phase3 results!) where he says that share price at $3.51 is "unsustainable" high.
Another classic (March 13 2013) is the article he wrote with his unnamed hedge fund manager who were shorting KERX at $7! I thing his buddy must be ex-hedge fund manager now.
Which one will buy Keryx? My very conservative estimate is that a dialysis provider can increase its profits at least $500M annually by acquiring Keryx. The estimate is based on IV Iron and ESA savings ($200M), royalty stream & upcoming milestones from Japan ($40M) and Europe ($60M), pre-dialysis potential ($190M), and tax loss carryforwards ($10M).
A7 results are the worst ever in biotech. DTIC was three times more effective than A7. The failed CEO has spent 15 years pumping this compound. Unbelievable. Whats wrong with you shareholders?
According to MLV potential suitors are Amgen, Sanofi, Takeda, Fresenius or DaVita. We will see.
I agree. Remember Ron`s backround. He used to be an investment banker not a scientist. He has received some modest cash compensations, but more importantly he owns over 800k shares + options. It is in his interest to find good exit deal.
A billion dollar company already. Winning pipeline. Six new abstracts...